Vorasidenib demonstrates 44.1-month median progression-free survival in Grade 2 IDH-Mutant Glioma, with 72% seizure reduction and durable disease control.

Elisrasib achieves 78% response rate in KRAS G12C NSCLC monotherapy, outperforming first-generation inhibitors in early Phase I/II data.

Ivonescimab plus chemo reduced death risk 34% versus PD-1 inhibitor in advanced squamous NSCLC, with OS benefit sustained at...

Daraxonrasib cuts death risk 60% in Phase 3 pancreatic cancer trial, doubling median overall survival versus chemotherapy in previously...

Apalutamide plus ADT reduced metastasis risk in Phase 3 trial, delaying subsequent therapy by over two years versus ADT...

Zenas BioPharma files FDA application for obexelimab in IgG4-RD, a B cell inhibitor showing 56% flare risk reduction in...

BioXcel's BXCL501 shows efficacy across severity levels in at-home agitation trial, with sustained benefit over 12 weeks of repeated...

ROADS phase 3 trial shows GammaTile intraoperative brachytherapy achieved 61.7% 24-month survival versus 35.7% for surgery plus radiotherapy in...

GRAIL's Galleri trial missed its primary endpoint for combined Stage III/IV cancer reduction but showed 26% Stage IV reduction...

Pumitamig achieves 72.7% response rate in Phase 2 squamous NSCLC trial, with 100% disease control across evaluable patients.